Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cohesion Technologies

This article was originally published in The Gray Sheet

Executive Summary

Private placement raises $4 mil. for Cohesion's NeuColl osteobiologics subsidiary to fund a pivotal clinical study of its NeuVisc osteoarthritis treatment and expand Collagraft synthetic bone graft substitute commercialization. The single injection NeuVisc treatment, if approved by FDA, would compete with currently available hyaluronic acid-based synovial fluid supplements that require multiple intra-articular knee injections. Also under development is NeuGraft, a second generation fully resorbable bone graft substitute and High Density Collagen for a variety of potential resorbable fixation applications. The financing reduces Cohesion's ownership position in NeuColl to "under 50%," Cohesion notes

You may also be interested in...



Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes

Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.

Singapore And Malaysia Test Joint Evaluation Of Generics

A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.

UsernamePublicRestriction

Register

MT013181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel